London-based Syncona saw a 77.9 million pound sterling ($98.6 million) decline in the valuation of its publicly listed life science companies over the first quarter of the year, which it attributed to “macro conditions as well as company-specific challenges.” The firm also name-checked the halving in value of its holding in SwanBio Therapeutics to 58.2 million pounds ($73.6 million) as a result of the biotech narrowing its focus to its lead program, a gene therapy for a spinal cord disorder. Source: Fierce Biotech 15/6/2023